Telavancin
Telavancin
Telavancin (pronounced: teh-la-van-sin) is a lipoglycopeptide antibiotic used in the treatment of certain bacterial infections. It is a semi-synthetic derivative of vancomycin, and was approved by the FDA in 2009.
Etymology
The name "Telavancin" is derived from its parent compound, vancomycin. The prefix "Tela-" is a reference to its semi-synthetic nature, indicating that it has been chemically modified from its original form.
Usage
Telavancin is used to treat serious skin infections caused by certain types of bacteria, including MRSA. It works by stopping the growth of bacteria.
Mechanism of Action
Telavancin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the cell wall precursor, inhibiting its polymerization. It also disrupts bacterial cell membrane function, leading to cell death.
Side Effects
Common side effects of Telavancin include nausea, vomiting, and diarrhea. Serious side effects may include kidney problems, hearing loss, and a severe allergic reaction known as anaphylaxis.
Related Terms
External links
- Medical encyclopedia article on Telavancin
- Wikipedia's article - Telavancin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski